Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of its original ...

Effective provider segmentation can make or break a new drug launch, and can also improve the lifecycle of existing portfolio ...

We live in a time of hope for millions around the world, as technological advancements and research breakthroughs hold the ...

In the 1980s, North Carolina emerged as a hub for biotechnology, largely due to the establishment of the North Carolina Biotechnology Center (NCBiotech). A state-supported, accelerator-style entity, ...

The brain cancer therapy recently approved by the FDA, Voranigo (vorasidenib), was developed from research by Duke University’s Darell Bigner and Johns Hopkins University's Bert Vogelstein and ...

E. Magnus Ohman, vice president of global development, general medicine, Amgen, reflects on the remarkable evolution of North Carolina's biotechnology sector, tracing its growth from humble origins to ...

Configurable FlexFactory™ biomanufacturing process trains can help scientists better control the production and processing of different viral vectors and new modalities—all within the same space. Plan ...

We live in an era of extraordinary scientific advancement, and as a result, we are seeing rapid growth in the development of new drugs. When the clinical trial ecosystem works, we deliver on our ...

Google’s global market leader for life sciences, Shweta Maniar, spoke with Life Science Leader about how large and small biopharmaceutical companies are using AI to lower costs and expedite timelines.

The rapid adoption of AI in the pharmaceutical market has led to a revolution in the research process and pharmaceutical development techniques. The AI revolution is not free of risks, however. This ...